Unknown

Dataset Information

0

Safety of tunneled central venous catheters in pediatric hematopoietic stem cell recipients with severe primary immunodeficiency diseases.


ABSTRACT: Tunneled central venous catheters (TCVCs) provide prolonged intravenous access for pediatric patients with severe primary immunodeficiency disease (PID) undergoing hematopoietic stem cell transplantation (HSCT). However, little is known about the epidemiology and clinical significance of TCVC-related morbidity in this particular patient group. We conducted the retrospective analysis of patients with severe PID who received percutaneous landmark-guided TCVC implantation prior to HSCT. We analyzed 92 consecutive TCVC implantations in 69 patients (median [interquartile range] age 3.0 [0-11] years) with severe combined immune deficiency (n = 39, 42.4%), chronic granulomatous disease (n = 17, 18.4%), and other rare PID syndromes (n = 36, 39.2%). The median length of TCVC observation was 144.1 (85.5-194.6) days with a total of 14,040 catheter days at risk (cdr). The overall rate of adverse events during catheter insertion was 17.4% (n = 16) and 25.0% during catheter dwell period (n = 23, catheter risk [CR] per 1000 cdr = 1.64). The most common complication was TCVC-related infection with an overall prevalence of 9.8% (n = 9, CR = 0.64), followed by late dislocation (n = 6, 6.5%, CR = 0.43), early dislocation (n = 4, 4.3%) and catheter dysfunction (n = 4, 4.3%, CR = 0.28). TCVCs are safe in children with severe PID undergoing HSCT with relatively low rates of TCVC-related infection.

SUBMITTER: Martynov I 

PROVIDER: S-EPMC7228048 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Safety of tunneled central venous catheters in pediatric hematopoietic stem cell recipients with severe primary immunodeficiency diseases.

Martynov Illya I   Klima-Frysch Jessica J   Kluwe Wolfram W   Engel Christoph C   Schoenberger Joachim J  

PloS one 20200515 5


Tunneled central venous catheters (TCVCs) provide prolonged intravenous access for pediatric patients with severe primary immunodeficiency disease (PID) undergoing hematopoietic stem cell transplantation (HSCT). However, little is known about the epidemiology and clinical significance of TCVC-related morbidity in this particular patient group. We conducted the retrospective analysis of patients with severe PID who received percutaneous landmark-guided TCVC implantation prior to HSCT. We analyzed  ...[more]

Similar Datasets

| S-EPMC8488503 | biostudies-literature
| S-EPMC6389340 | biostudies-literature
| S-EPMC2292495 | biostudies-other
| S-EPMC5610787 | biostudies-literature
| S-EPMC6302318 | biostudies-literature
| S-EPMC10885060 | biostudies-literature
| S-EPMC10577359 | biostudies-literature
| S-EPMC10631277 | biostudies-literature
| S-EPMC9124179 | biostudies-literature
| S-EPMC6994843 | biostudies-literature